Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
Recruiting · NCT06337695 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer | Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, colitis, colonic disorder, diarrheal disease, digestive system disorder, gastroenteritis, intestinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-08-27 | NCT06337695 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AHS Cancer Control Alberta | 37 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Arthur J.E. Child Comprehensive Cancer Centre | Calgary | Canada | 45 |
| Cross Cancer Institute | Edmonton | Canada | 146 |